👍👍👍_老虎社区_美港股上老虎

Champion365
2021-11-08

👍👍👍

Alcon agrees $475 million deal to buy U.S. eye surgery company Ivantis<blockquote>爱尔康同意以4.75亿美元收购美国眼科手术公司Ivantis</blockquote>

ZURICH, Nov 8 (Reuters) - Alcon has agreed to buy Ivantis, the maker of a tiny stent to treat glauco

Alcon agrees $475 million deal to buy U.S. eye surgery company Ivantis<blockquote>爱尔康同意以4.75亿美元收购美国眼科手术公司Ivantis</blockquote>

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":845544162,"tweetId":"845544162","gmtCreate":1636355721783,"gmtModify":1636355722581,"author":{"id":3573653602271971,"idStr":"3573653602271971","authorId":3573653602271971,"authorIdStr":"3573653602271971","name":"Champion365","avatar":"https://static.tigerbbs.com/04df800589718231e24e96f7a0b551cc","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":54,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body>👍👍👍</body></html>","htmlText":"<html><head></head><body>👍👍👍</body></html>","text":"👍👍👍","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/845544162","repostId":1165168470,"repostType":4,"repost":{"id":"1165168470","kind":"news","pubTimestamp":1636354224,"share":"https://www.laohu8.com/m/news/1165168470?lang=zh_CN&edition=full","pubTime":"2021-11-08 14:50","market":"us","language":"en","title":"Alcon agrees $475 million deal to buy U.S. eye surgery company Ivantis<blockquote>爱尔康同意以4.75亿美元收购美国眼科手术公司Ivantis</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1165168470","media":"Reuters","summary":"ZURICH, Nov 8 (Reuters) - Alcon has agreed to buy Ivantis, the maker of a tiny stent to treat glauco","content":"ZURICH, Nov 8 (Reuters) - Alcon has agreed to buy Ivantis, the maker of a tiny stent to treat glaucoma, for an initial $475 million, the Swiss eye care company said on Monday.<blockquote>路透苏黎世11月8日-瑞士眼科护理公司爱尔康周一表示，已同意以4.75亿美元的初始价格收购治疗青光眼的微型支架制造商Ivantis。</blockquote> Privately held Ivantis Hydrus Microstent makes a minimally-invasive glaucoma surgery (MIGS) device designed to lower intraocular pressure for open-angle glaucoma patients in connection with cataract surgery.<blockquote>私人持有的Ivantis Hydrus Microstent生产一种微创青光眼手术（MIGS）设备，旨在降低与白内障手术相关的开角型青光眼患者的眼内压。</blockquote> The microstent, roughly the size of an eyelash, reduces eye pressure by re-establishing flow through Schlemm's canal, the eye's natural outflow pathway, Alcon said.<blockquote>爱尔康表示，这种微型支架大约有睫毛大小，通过重建通过施莱姆管（眼睛的自然流出路径）的流动来降低眼压。</blockquote> Glaucoma is the second-largest cause of blindness after cataracts, affecting more than 75 million people globally, it added.<blockquote>报告补充说，青光眼是仅次于白内障的第二大致盲原因，影响着全球超过7500万人。</blockquote> The Swiss company, which spun off from Novartis in 2019, said the deal for California-based Ivantis strengthened its portfolio of treatments for cataract, refractive, retina and glaucoma patients.<blockquote>这家于2019年从诺华分拆出来的瑞士公司表示，与总部位于加州的Ivantis的交易加强了其针对白内障、屈光、视网膜和青光眼患者的治疗组合。</blockquote> It cited a study showed 65% of Hydrus Microstent patients remained medication-free at five years after having the stent implanted.<blockquote>它引用了一项研究，显示65%的Hydrus微型支架患者在植入支架后五年仍未接受药物治疗。</blockquote> Alcon said it may be required to make additional payments upon the achievement of certain regulatory and commercial milestones.<blockquote>爱尔康表示，在达到某些监管和商业里程碑后，可能需要支付额外费用。</blockquote> The transaction is anticipated to close in the first quarter of 2022 subject to customary closing conditions, including regulatory approval, it added.<blockquote>它补充说，该交易预计将于2022年第一季度完成，但须满足惯例成交条件，包括监管部门的批准。</blockquote>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alcon agrees $475 million deal to buy U.S. eye surgery company Ivantis<blockquote>爱尔康同意以4.75亿美元收购美国眼科手术公司Ivantis</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlcon agrees $475 million deal to buy U.S. eye surgery company Ivantis<blockquote>爱尔康同意以4.75亿美元收购美国眼科手术公司Ivantis</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nReuters2021-11-08 14:50\n\n</h4>\n</header>\n<article>\nZURICH, Nov 8 (Reuters) - Alcon has agreed to buy Ivantis, the maker of a tiny stent to treat glaucoma, for an initial $475 million, the Swiss eye care company said on Monday.<blockquote>路透苏黎世11月8日-瑞士眼科护理公司爱尔康周一表示，已同意以4.75亿美元的初始价格收购治疗青光眼的微型支架制造商Ivantis。</blockquote> Privately held Ivantis Hydrus Microstent makes a minimally-invasive glaucoma surgery (MIGS) device designed to lower intraocular pressure for open-angle glaucoma patients in connection with cataract surgery.<blockquote>私人持有的Ivantis Hydrus Microstent生产一种微创青光眼手术（MIGS）设备，旨在降低与白内障手术相关的开角型青光眼患者的眼内压。</blockquote> The microstent, roughly the size of an eyelash, reduces eye pressure by re-establishing flow through Schlemm's canal, the eye's natural outflow pathway, Alcon said.<blockquote>爱尔康表示，这种微型支架大约有睫毛大小，通过重建通过施莱姆管（眼睛的自然流出路径）的流动来降低眼压。</blockquote> Glaucoma is the second-largest cause of blindness after cataracts, affecting more than 75 million people globally, it added.<blockquote>报告补充说，青光眼是仅次于白内障的第二大致盲原因，影响着全球超过7500万人。</blockquote> The Swiss company, which spun off from Novartis in 2019, said the deal for California-based Ivantis strengthened its portfolio of treatments for cataract, refractive, retina and glaucoma patients.<blockquote>这家于2019年从诺华分拆出来的瑞士公司表示，与总部位于加州的Ivantis的交易加强了其针对白内障、屈光、视网膜和青光眼患者的治疗组合。</blockquote> It cited a study showed 65% of Hydrus Microstent patients remained medication-free at five years after having the stent implanted.<blockquote>它引用了一项研究，显示65%的Hydrus微型支架患者在植入支架后五年仍未接受药物治疗。</blockquote> Alcon said it may be required to make additional payments upon the achievement of certain regulatory and commercial milestones.<blockquote>爱尔康表示，在达到某些监管和商业里程碑后，可能需要支付额外费用。</blockquote> The transaction is anticipated to close in the first quarter of 2022 subject to customary closing conditions, including regulatory approval, it added.<blockquote>它补充说，该交易预计将于2022年第一季度完成，但须满足惯例成交条件，包括监管部门的批准。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://finance.yahoo.com/news/1-alcon-agrees-475-million-062954688.html\">Reuters</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ALC":"Alcon Inc"},"source_url":"https://finance.yahoo.com/news/1-alcon-agrees-475-million-062954688.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1165168470","content_text":"ZURICH, Nov 8 (Reuters) - Alcon has agreed to buy Ivantis, the maker of a tiny stent to treat glaucoma, for an initial $475 million, the Swiss eye care company said on Monday.\nPrivately held Ivantis Hydrus Microstent makes a minimally-invasive glaucoma surgery (MIGS) device designed to lower intraocular pressure for open-angle glaucoma patients in connection with cataract surgery.\nThe microstent, roughly the size of an eyelash, reduces eye pressure by re-establishing flow through Schlemm's canal, the eye's natural outflow pathway, Alcon said.\nGlaucoma is the second-largest cause of blindness after cataracts, affecting more than 75 million people globally, it added.\nThe Swiss company, which spun off from Novartis in 2019, said the deal for California-based Ivantis strengthened its portfolio of treatments for cataract, refractive, retina and glaucoma patients.\nIt cited a study showed 65% of Hydrus Microstent patients remained medication-free at five years after having the stent implanted.\nAlcon said it may be required to make additional payments upon the achievement of certain regulatory and commercial milestones.\nThe transaction is anticipated to close in the first quarter of 2022 subject to customary closing conditions, including regulatory approval, it added.","news_type":1,"symbols_score_info":{"ALC":0.9}},"isVote":1,"tweetType":1,"viewCount":2671,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":6,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}